Tumor Biology

, Volume 37, Issue 4, pp 5475–5484 | Cite as

Association of promoter polymorphisms of Fas –FasL genes with development of Chronic Myeloid Leukemia

  • Prajitha Mohandas Edathara
  • Manjula Gorre
  • Sailaja Kagita
  • Sugunakar Vuree
  • Anuradha Cingeetham
  • Santhoshi Rani Nanchari
  • Phanni bhushann Meka
  • Sandhya Annamaneni
  • Raghunadha Rao Digumarthi
  • Vishnupriya Satti
Original Article


Chronic myeloid leukemia (CML) is a monoclonal myeloproliferative disorder of hematopoietic stem cells (HSCs), characterized by reciprocal translocation, leading to the formation of BCR-ABL oncogene with constitutive tyrosine kinase (TK) activity. This oncogene is known to deregulate different downstream pathways which ultimately lead to cell proliferation, defective DNA repair, and inhibition of apoptosis. Fas (Fas cell surface death receptor) is a member of tumor necrosis factor (TNF) superfamily which interacts with its ligand, FasL, to initiate apoptosis. Promoter polymorphisms in Fas-FasL genes are known to influence the apoptotic signaling. Hence, the present study has been aimed to find out the association of the promoter polymorphisms in Fas and FasL genes with the development and progression of CML. Blood samples from 772 subjects (386 controls and 386 cases) were collected and genotyped for Fas-FasL gene polymorphisms through PCR-RFLP method. The association between SNPs and clinical outcome was analyzed using statistical softwares like SPSS version 20, SNPSTATs, and Haploview 2.1. The study revealed a significant association of Fas −670 G>A and FasL −844 T>C polymorphisms with the development of CML while Fas −670 AG was associated with accelerated phase. Combined risk analysis by taking the risk genotypes in cases and controls revealed a significant increase in CML risk with increase in number of risk genotypes (one risk genotype—OR 1.99 (1.44–2.76), p < 0.0001; two risk genotypes—OR 3.33 (1.91–5.81), p < 0.0001). Kaplan–Meier survival analysis of Fas −670 A>G and FasL −844 T>C showed reduced event-free survival in patients carrying the variant genotypes, Fas −670 GG, 32.363 ± 6.33, and FasL −844 CC, 33.489 ± 5.83, respectively. Our findings revealed a significant association of Fas −670 GG, FasL −844 TC, and CC genotypes with increased risk of CML.


Fas Fas L Chronic Myeloid Leukemia Promoter polymorphism 



We are grateful to the Council of Scientific Research-Extra Mural Research (CSIR-EMR-II) project (vide no-027/ (0258)/12/EMR-II) and Osmania University-Department of Science and Technology (OU-DST)-PURSE program, Osmania University, for the financial assistance to carry out the research work. We would like to express our deep gratitude to all the patients and volunteers who participated in the study.

Compliance with ethical standards

Conflicts of interest


Supplementary material

13277_2015_4295_MOESM1_ESM.docx (22 kb)
Supplementary tables (DOCX 22 kb)


  1. 1.
    Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Cirinna M, Trotta R, Salomoni P, Kossev P, Wasik M, et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood. 2000;96(12):3915–21.PubMedGoogle Scholar
  3. 3.
    Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449e56.CrossRefGoogle Scholar
  4. 4.
    Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med. 2002;78:312e25.Google Scholar
  5. 5.
    Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv. 2000;74:281–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Gross N, Balmas K, Beretta BC, Tschopp J. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma. Med Pediatr Oncol. 2001;36:111–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169e78.CrossRefGoogle Scholar
  8. 8.
    Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34:577–82.CrossRefPubMedGoogle Scholar
  9. 9.
    Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63:4327–30.PubMedGoogle Scholar
  10. 10.
    Wu J, Metz C, Xu X, Abe R, Gibson AW, et al. A novel polymorphic CAAT/enhancer-binding protein element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170:132–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang W, Li C, Wang J, He C. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepato-Gastroenterology. 2012;59:141–6.PubMedGoogle Scholar
  12. 12.
    Hashemi M, Fazaeli A, Ghavami S, Eskandari NE, Arbabi F, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer -pilot study of 134 cases. PLoS One. 2013;8, e53075.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bye H, Prescott NJ, Matejcic M, Rose E, Lewis CM, et al. Population specific genetic associations with oesophageal squamous cell carcinoma in South Africa. Carcinogenesis. 2011;32:1855–61.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Qureshi A, Nan H, Dyer M, Han J. Polymorphisms of FAS and FAS ligand genes and risk of skin cancer. J Dermatol Sci. 2010;58:78–80.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li Y, Hao YL, Kang S, Zhou RM, Wang N, et al. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Mandal RK, Mittal RD. Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol Oncol. 2012;30:555–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hu Z, Li C, Chen K, Wang LE, Sturgis EM, et al. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol. 2008;1–8.Google Scholar
  19. 19.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.CrossRefPubMedGoogle Scholar
  20. 20.
    Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992;267:10709–15.PubMedGoogle Scholar
  22. 22.
    Behrmann HW, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994;24(12):3057–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol. 1994;6(10):1567–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Li K, Wusheng L, Huawei Z, Li Z. Association between FAS 1377G>A polymorphism and breast cancer susceptibility: a meta-analysis. Tumor Biol. 2014;35:351–6.CrossRefGoogle Scholar
  25. 25.
    Zeng J, Yi F, Peiyu L. FAS −1377 A/G polymorphism in breast cancer: a meta-analysis. Tumor Biol. 2014;35:2575–81.CrossRefGoogle Scholar
  26. 26.
    Xu Y, Bangshun H, Rui L, Yuqin P, Tianyi G, et al. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One. 2014;9(3), e90090.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    JaeYP LWK, Jung DK, Choi JE, Park JI, et al. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res. 2009;15:1794–800.CrossRefGoogle Scholar
  28. 28.
    Behnaz V, Zahra A, Hossein G, Reza H, Fatemeh MK. Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis. Pathol Oncol Res. 2014;20:367–74.CrossRefGoogle Scholar
  29. 29.
    Dapeng L, Erich MS, Wang LE, Zhensheng L, Mark E, et al. FAS and FASLG genetic variants and risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1484–91.CrossRefGoogle Scholar
  30. 30.
    Zhang Z, Wang LE, Erich MS, Adel KEN, Waun KH, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12:5596–602.CrossRefPubMedGoogle Scholar
  31. 31.
    Sun T, Xiaoping M, Xuemei Z, Wen T, Ping X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96(13):1030–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhao H, Linfeng Z, Xinru L, Lifang W. FasL gene -844T/C mutation of esophageal cancer in south China and its clinical significance. Sci Rep. 2014;4:3866. doi: 10.1038/srep03866.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Prajitha Mohandas Edathara
    • 1
  • Manjula Gorre
    • 1
  • Sailaja Kagita
    • 2
  • Sugunakar Vuree
    • 1
  • Anuradha Cingeetham
    • 1
  • Santhoshi Rani Nanchari
    • 1
  • Phanni bhushann Meka
    • 1
  • Sandhya Annamaneni
    • 1
  • Raghunadha Rao Digumarthi
    • 2
  • Vishnupriya Satti
    • 1
  1. 1.Department of GeneticsOsmania UniversityHyderabadIndia
  2. 2.Homi Bhabha Cancer Hospital and Research CentreVisakhapatnamIndia

Personalised recommendations